Healthcare Equipment and Supplies
Company Overview of NeoTract, Inc.
NeoTract, Inc. develops and manufactures minimally invasive medical devices that address unmet needs in the field of urology. It offers UroLift System, a minimally invasive device to treat the men suffering from an enlarged prostate; relieve prostate obstruction and open the urethra; and relieve lower urinary tract symptoms due to benign prostatic hyperplasia. Its products are available throughout the United States, Europe, Australia, Canada, Mexico, and South Korea. The company was founded in 2004 and is based in Pleasanton, California with business locations in the United States, Australia, Europe, Denmark, Finland, Germany, Italy, the Netherlands, Norway, Spain, Sweden, Turkey, and the Un...
4473 Willow Road
Pleasanton, CA 94588
Founded in 2004
Key Executives for NeoTract, Inc.
Chief Executive Officer, President and Director
Founder, Chief Technical Officer and Director
Co-Founder and Vice President of Professional Education
Compensation as of Fiscal Year 2016.
NeoTract, Inc. Key Developments
NeoTract Announces Availability of UroLift System
Jul 7 16
NeoTract, Inc. announced the recent addition of several new insurance positive coverage decisions to expand access to the UroLift® System as a covered benefit for many more men across the United States, including Medicare, Medicaid and commercial insurance beneficiaries. Recently, a positive coverage decision was issued by Medicare administrative contractor National Government Services, Inc. (NGS), for beneficiaries in the states of Connecticut, Illinois, Maine, Massachusetts, Minnesota, New Hampshire, New York, Rhode Island, Vermont and Wisconsin. The UroLift System was also made available to beneficiaries of independent networks, such as Kaiser Permanente and SelectHealth, as well as numerous Blue Cross Blue Shield plans, such as CareFirst, Highmark, Louisiana, Nebraska and South Carolina. The UroLift System provides a unique approach to treating BPH that lifts and holds the enlarged prostate tissue out of the way so it no longer blocks the urethra. UroLift is the only BPH procedure that does not require cutting, heating or removal of the prostate tissue. Symptoms of BPH often include sleepless nights and urinary problems, and can cause loss of productivity, depression and decreased quality of life. Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of medication treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts, burns or ablates prostate tissue to open the blocked urethra. While current surgical options can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction and retrograde ejaculation (dry orgasm).
NeoTract, Inc. Presents at Medical Device Conference, Jun-23-2016
Jun 15 16
NeoTract, Inc. Presents at Medical Device Conference, Jun-23-2016. Venue: Sharon Heights Golf and Country Club, 2900 Sand Hill Road, Menlo Park, CA, United States. Presentation Date & Speakers: Jun-24-2016, David Amerson, Chief Executive Officer, President and Director, Ted Lamson, Founder, Chief Technical Officer and Director.
NeoTract, Inc. Announces Enrollment of First Patients in MedLift U.S. IDE trial
Mar 7 16
NeoTract, Inc. announced that the first patients have been enrolled in the MedLift™ U.S. IDE trial. The MedLift IDE trial is a new study that will be conducted across eight U.S. sites. The study is designed to demonstrate safety and effectiveness of the UroLift® System for the treatment of patients with benign prostatic hyperplasia (BPH) who have an obstructive median lobe, which is currently contraindicated in the United States. Obstructive median lobes are present in approximately 5% to 10% of BPH patients who would otherwise be eligible for treatment with the UroLift System. Unlike other BPH procedures, the UroLift System directly opens the urethra without cutting, heating, or removing prostate tissue. In this way patients experience very rapid and durable relief. This new clinical study will continue to advance its understanding of the benefits of the UroLift System.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|